SAN DIEGO, Aug. 3, 2011 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months and six months ended June 30, 2011. Revenues were $0.8 million for the second quarter of 2011 compared with $2.1 million for the second quarter of 2010, reflecting the 2010 shipment of dengue vaccine manufactured for the U.S. Navy, and the completion in 2010 of Allovectin® Phase 3 trial funding under the company's research and development agreement with AnGes MG, Inc. Operating expenses were $9.3 million for the second quarter of 2011 compared with $10.6 million for the second quarter of 2010, reflecting reduced costs for the company's Allovectin® Phase 3 and TransVax™ Phase 2 clinical trials. The net loss was $8.4 million, or $0.12 per share, for the second quarter of 2011, compared with $8.4 million, or $0.15 per share, for the second quarter of 2010.
